Volume 8, Supplement 2Review ArticlesThe Treatment of Hormone-Refractory Prostate Cancer: Docetaxel and Beyond16th International Prostate Cancer UpdateDaniel P PetrylakTwo randomized clinical trials demonstrated a survival benefit of 20% to 24% with docetaxel-based therapy when compared with survival with mitoxantrone and prednisone after failure of androgen ablation therapy. These studies supported the approval of docetaxel-based therapy for the treatment of metastatic hormone-refractory prostate cancer by the US Food and Drug Administration in May 2005. Clinical trials in hormone-refractory prostate cancer are now focused on building on the survival improvement seen with docetaxel-based therapy. This article presents a summary of some of the more promising treatments and regimens for advanced prostate cancer. [Rev Urol. 2006;8(suppl 2):S48-S55]Prostate cancerProstate-specific antigenAndrogen ablationDocetaxelEstramustineEndothelin receptor antagonist